(CercleFinance.com) – Remix Therapeutics announced on Wednesday the conclusion of a collaboration and licensing agreement with Roche relating to the development of small therapeutic molecules targeting RNA.
In a statement, Roche said it was impressed by the scientific performance of Remix’s drug discovery platform, called ‘REMaster’.
Under the terms of the agreement, Remix and Roche will jointly conduct preclinical activities while Roche will have an exclusive option to potentially commercialize the product that could result from their collaboration.
Remix is expected to receive an upfront payment of $30 million, which could be accompanied by up to $12 million in milestone payments.
Factoring in possible royalties, the deal could be worth nearly $1 billion.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
